The Spectrum of Atm Gene Mutations in Iranian Patients With Ataxia-Telangiectasia Publisher Pubmed



Amirifar P^{1, 2} ; Ranjouri MR² ; Pashangzadeh S² ; Lavin M³ ; Yazdani R² ; Moeini Shad T^{2, 4} ; Mehrmohamadi M⁵ ; Salami F² ; Delavari S² ; Moamer S⁶ ; Aghamohammadi A² ; Akrami SM¹ ; Abolhassani H^{2, 7} Show Affiliations
Source: Pediatric Allergy and Immunology Published:2021

Abstract

Background: Ataxia-telangiectasia (A-T) is a rare genetic disorder characterized by a distinct range of clinical manifestations, including progressive ataxia, immunodeficiency, and radiosensitivity. Methods: Clinical data, laboratory results, and genetic data were collected from forty-three A-T patients. Whole-exome sequencing and Sanger sequencing were done for the patients clinically diagnosed as suffering from A-T. Based on the phenotype severity of the disease, patients were divided into severe and mild subgroups. Results: The median (IQR) age of diagnosis in this cohort was 5 (3-7) years, and various types of clinical manifestations, including fever (P =.005), lower respiratory tract infection (P =.033), diarrhea (P =.014), and hepatosplenomegaly (P =.032), were significantly higher among patients diagnosed with the severe phenotype. Our results showed a correlation between phenotype severity and mutation type. The chance of having severe phenotype in patients who have severe mutations, including frameshift and nonsense, was 7.3 times higher than in patients who were categorized in the mild genotype group (odds ratio = 7.3, P =.006). Thirty-four types of mutations including 9 novel mutations were observed in our study. Conclusion: Molecular analysis provides the opportunity for accurate diagnosis and timely management in A-T patients with chronic progressive disease, especially infections and the risk of malignancies. This study characterizes for the first time the broad spectrum of mutations and phenotypes in Iranian A-T patients, which is required for carrier detection and reducing the burden of disease in the future using the patients’ families and for the public healthcare system. © 2021 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.